Rendic, S. and Guengerich, F.P. (2010) Update Information on Drug Metabolism Systems—2009, Part II: Summary of Information on the Effects of Diseases and Environmental Factors on Human Cytochrome P450 (CYP) Enzymes and Transporters. Current Drug Metabolism, 11, 4-84.
https://doi.org/10.2174/138920010791110917

has been cited by the following article:

• TITLE: Ulipristal Acetate (UPA): An Alternative Option to Surgery for Uterine Fibroids in Reproductive Age: A Review

  AUTHORS: Subash Chandra Sharma, Cunjian Yi

  KEYWORDS: Myoma, Females, Uterine Fibroids, Selective Progesterone Receptor Modulator (SPRM), Ulipristal Acetate (UPA)

  JOURNAL NAME: Yangtze Medicine, Vol.6 No.1, March 31, 2022

  ABSTRACT: Uterine fibroids are common in females of reproductive age and substantially affecting fertility and quality of life. Current management strategies mainly involve surgical interventions. For treatment, options available are surgical and non-surgical, but the mode of management leans on several factors, such as severity of symptoms, patient’s age, myoma characteristics, desire to preserve uterus and fertility. Alternative approach to surgery for the treatment of symptomatic females with uterine myomas has been recognized. Ulipristal acetate (UPA) has been the first selective progesterone-receptor modulator (SPRM) approved for the pre-operative and long-term management of uterine fibroids. There are evidences promoting an important role for progesterone pathways in the pathophysiology of uterine fibroids which supports the use of ulipristal acetate. The availability of alternative choices to surgical intervention is very necessary especially for those willing to preserve uterus and fertility. One of the alternatives is with ulipristal acetate, which has been proven to treat fibroid symptoms effectively.